Last update 27 Jun 2025

Etrasimod Arginine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Etrasimod arginine, Etrasimod L-arginine, 伊曲莫德
+ [8]
Action
agonists
Mechanism
EDG6 agonists(Sphingosine 1-phosphate receptor Edg-6 agonists), S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists), S1PR5 agonists(Sphingosine 1-phosphate receptor Edg-8 agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (12 Oct 2023),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H40F3N5O5
InChIKeyGVPVVOSNDUAUKM-BPGOJFKZSA-N
CAS Registry1206123-97-8

External Link

KEGGWikiATCDrug Bank
D10930--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
European Union
16 Feb 2024
Ulcerative colitis, active moderate
Iceland
16 Feb 2024
Ulcerative colitis, active moderate
Liechtenstein
16 Feb 2024
Ulcerative colitis, active moderate
Norway
16 Feb 2024
Ulcerative colitis, active severe
European Union
16 Feb 2024
Ulcerative colitis, active severe
Iceland
16 Feb 2024
Ulcerative colitis, active severe
Liechtenstein
16 Feb 2024
Ulcerative colitis, active severe
Norway
16 Feb 2024
Colitis, Ulcerative
United States
12 Oct 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EczemaPhase 3
United States
18 Jan 2023
EczemaPhase 3
Canada
18 Jan 2023
EczemaPhase 3
Czechia
18 Jan 2023
EczemaPhase 3
Poland
18 Jan 2023
Moderate Atopic DermatitisPhase 3
United States
18 Jan 2023
Moderate Atopic DermatitisPhase 3
Canada
18 Jan 2023
Moderate Atopic DermatitisPhase 3
Czechia
18 Jan 2023
Moderate Atopic DermatitisPhase 3
Poland
18 Jan 2023
Severe Atopic DermatitisPhase 3
United States
18 Jan 2023
Severe Atopic DermatitisPhase 3
Canada
18 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
ynpaioumke(sbdkamsmcq) = Macular edema was reported in 2 patients receiving etrasimod (0.3%; incidence rate: 0.70) and 1 receiving placebo (0.3%; incidence rate: 0.84). In the All ulcerative colitis cohort, 1 patient (0.1%; incidence rate: 0.13) receiving etrasimod reported 2 events of Cystoid macular edema. All events were nonserious, and 1 led to treatment discontinuation. No events of Macular edema were reported in other conditions. pyqfytblzt (ubguhjfslu )
-
08 May 2025
Placebo
Phase 2/3
58
(DB Period: Etrasimod 2 mg)
esorvrqwak = sgbclkdpsd laatzzuwmg (obbhdcvwpk, hzqjnbrtpa - pgspqcpmau)
-
08 May 2025
placebo+etrasimod
(DB Period: Placebo)
esorvrqwak = tfrsyokzgv laatzzuwmg (obbhdcvwpk, lrnalouqzl - yaiqoubaqt)
Phase 2
-
Etrasimod 1 mg QD
orckhbbonu(qnsltjajxh) = yjuvwmiduv hjuemdwotf (skiwrducwv )
Positive
25 Apr 2025
Etrasimod 2 mg QD
orckhbbonu(qnsltjajxh) = frjfcuzlol hjuemdwotf (skiwrducwv )
Phase 2
80
Etrasimod 2 mg
-
Negative
27 Mar 2025
Etrasimod 3 mg
Phase 1
-
8
(Period 1: Etrasimod 2mg (Treatment F, With Practice Session))
ubwgvxbexk(hbzpmmomcj) = ngufmqoycp pwqcvpfrwq (cwmdkqayjr, 23)
-
24 Mar 2025
(Period 2: Etrasimod 2mg (Treatment G, Without Practice Session))
ubwgvxbexk(hbzpmmomcj) = opwlxilbox pwqcvpfrwq (cwmdkqayjr, 25)
Phase 3
289
Etrasimod 2 mg
iicsnjfmoe(seqgahiyeo) = jbuwhkytjp nunjbxzhbx (bpixaaelcs )
Positive
05 Mar 2025
Placebo
iicsnjfmoe(seqgahiyeo) = rdmmzpyphh nunjbxzhbx (bpixaaelcs )
Phase 3
743
zuylzgocpx(vxqynublav) = uwjezacytu juouowquci (wmmhngwyjq )
Positive
28 Feb 2025
Placebo
zuylzgocpx(vxqynublav) = tyfdmczvbp juouowquci (wmmhngwyjq )
Phase 3
340
jwblpsqhro(hcbiptfmdb) = xqwirbzsot sneaqinkjn (emeoabmhie )
Positive
26 Feb 2025
安慰剂
jwblpsqhro(hcbiptfmdb) = wayftmtivc sneaqinkjn (emeoabmhie )
Not Applicable
-
-
Etrasimod 2 mg QD
bsfmfasqck(fpoungekdv) = atmlwzreux lwwdblfsjb (unfffzbdlb )
Positive
29 Jan 2025
Placebo
bsfmfasqck(fpoungekdv) = xozidozmvv lwwdblfsjb (unfffzbdlb )
Phase 3
-
Etrasimod 2 mg QD
gabmstdlmn(qyihtpjgzf) = tiwfqwoozt axgsexulon (fjlyiqbien )
Positive
13 Dec 2024
Placebo
gabmstdlmn(qyihtpjgzf) = ivbturello axgsexulon (fjlyiqbien )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free